Published on | 2 months ago
Programmes ERCThe ERC is dedicated to funding frontier research that explores uncharted territories, fosters interdisciplinary collaboration, and pushes the boundaries of knowledge. This research often leads to valuable insights and practical applications that address complex global challenges, benefiting society as a whole.
Explore the section below to discover how ERC-funded projects transcend the mere advancement of scientific and technological knowledge. This section includes comprehensive reports derived from various analyses outlining how ERC’s portfolio contributes to major EU policy priorities. The groundbreaking research supported by the ERC has nurtured the development of innovative approaches that have the potential to positively impact various aspects of our lives.
Contribution to policies
Exploring ERC Frontier Research
--> A summary of the findings can be found in this ERC press release (July 2022).
Taken from Mapping ERC Frontier Research: an overview (ERC website)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.